Previous 10 | Next 10 |
Avalon GloboCare ( AVCO -6.4% ) completes Phase I first-in-human clinical study of its lead Chimeric Antigen Receptor (CAR) T-cell therapy candidate, AVA-001. More news on: Avalon GloboCare Corp., Healthcare stocks news, Read more ...
- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia - Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity or Adverse Side Effects; Successfully “Bridging” to Allogeneic Bone Mar...
Avalon GloboCare (NASDAQ: AVCO ) is up 7% after announcing a strategic partnership University of Natural Resources and Life Sciences (BOKU) to advance intranasal and oral COVID-19 vaccine candidate. More news on: Avalon GloboCare Corp., Healthcare stocks news, Stocks on the m...
- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a novel S-layer SARS-CoV-2 (COVID-19) vaccine - Avalon and BOKU have already begun to develop a nov...
FREEHOLD, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that the Company has appointed Professor Uwe B. Sleytr to its Scientific and Clinical Advisory Board. Pr...
FREEHOLD, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has entered into a three-way material transfer agreement (MTA) with Weill Cornell Medicine in New Y...
Avalon GloboCare ( AVCO +7.8% ) announced strategic partnership with GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, Antibody-Based IgG/IgM and PCR-Based SARS-CoV-2 Detection Systems. More news on: Avalon GloboCare Corp., Healthcare stocks news, R...
Entered Into Strategic Partnership with GensKey Medical Technology Co. Ltd. to Co-Develop and Commercialize Point-of-Care Antibody-Based IgG/IgM and PCR-Based SARS-CoV-2 Detection Systems, Both of Which are CE Mark Certified and Pending FDA Emergency Use Authorization (EUA) Initiate...
RNA-Based Chimeric Antigen Receptor (CAR) Design Compatible with Broad Range of Immune Effector Cells, Including T (CAR-T) and Natural Killer Cells (CAR-NK) Without the Use of Viral Vectors Capable of Targeting Multiple Tumor Antigens for Potentially Superior Therapeutic Effects R...
Focused on Novel Combination of Clinical-Grade Exosomes and Hydropeptides for Cosmeceutical and Orthopedic Product Development Signed Three-Way Material Transfer Agreement between Avalon GloboCare, HydroPeptide and Weill Cornell Medicine FREEHOLD, N.J., April 28, 2020 (GLOBE...
News, Short Squeeze, Breakout and More Instantly...
Avalon GloboCare Corp. Company Name:
AVCO Stock Symbol:
NASDAQ Market:
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon...
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a ...
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ: AVCO) , a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Ch...